Skip to content

Thyroid Eye Disease Now Has an At-Home Injection Option

Thyroid eye disease (TED) can be one of the most distressing conditions a patient faces, because it affects both how the eyes work and how a person looks. The FDA has now approved a new treatment that patients can give themselves at home, and it is worth understanding what that means.

What thyroid eye disease is

TED is an autoimmune condition linked to thyroid disease. According to Genentech, it affects about 150 out of every 100,000 people in the U.S., most of them women of working age. Tissue builds up behind the eye and pushes it forward (proptosis). That can cause double vision, discomfort, and sometimes pain or vision loss. Because the change in appearance can be dramatic, many patients also struggle with depression, anxiety, or social withdrawal.

What the FDA approved

The FDA approved Enspryng (satralizumab-mwge, Genentech/Roche), an interleukin-6 inhibitor, for TED. It is injected under the skin and can be given by patients or caregivers after training, making it the first at-home subcutaneous treatment approved for TED. The drug was already approved for neuromyelitis optica spectrum disorder, a different autoimmune condition.

What the trials showed

  • In the phase 3 SatraGO-2 trial, in patients with active and chronic moderate-to-severe TED, 52.9% of patients on Enspryng had a proptosis response compared with 23.4% on placebo.
  • Double vision improved in 60.7% on Enspryng versus 25.8% on placebo.
  • A companion trial, SatraGO-1, missed its primary goal at week 24.
  • In both trials, safety was consistent with the drug’s known profile.

Enspryng becomes the third FDA-approved treatment for TED, joining Tepezza and Lumvoa. Other available therapies include corticosteroids, immunosuppressants, and other biologics. Because Enspryng can be given at home, it may be a convenient option for some patients.

Signs to bring to your doctor

  • Eyes that look more prominent or “staring”
  • Puffy or retracted eyelids
  • Double vision, especially when looking up or to the side
  • A gritty feeling, redness, or pressure behind the eyes
  • Any change in color vision or sharpness, which needs urgent attention

Our role

Khanna Vision Institute does not treat thyroid eye disease. TED is usually managed by an oculoplastic or orbit specialist working with an endocrinologist. When we see signs of TED during an exam at our Beverly Hills office, we refer patients to the right specialist and help coordinate care. The best treatment choice depends on whether the disease is active, how severe it is, and your overall health.

If you are interested in how conditions elsewhere in the body show up in the eyes, you will find more at 1800realdoctor.com.

Source: FDA approves Enspryng for thyroid eye disease (Healio Ophthalmology, 10/16/2026 (updated 10/21/2026)). This article is an educational summary written by Khanna Vision Institute and is not a substitute for medical advice.